Non-Cytologic Cervical Screening Is Cost-Effective – NEJM Study
This article was originally published in The Gray Sheet
Executive SummaryStrategies such as visual inspection of the cervix or the use of human papillomavirus assays that require only one or two clinical visits are cost-effective alternatives to conventional three-visit cytology-based screening in low-resource settings, according to a study published in the Nov. 17 New England Journal of Medicine
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).